Covid-19: Some hope of triumph in vaccine clinical tests
An engineer works at the Quality Control Laboratory on an experimental vaccine for the Covid-19 at the Sinovac Biotech facilities in Beijing on April 29, 2020. PHOTO | NICOLAS ASFOURI
The ChAdOx1 nCoV-19 vaccine has shown promising results in its final phase of clinical trial.
AstraZeneca has partnered with several countries to make over two billion doses of the vaccine which has been found to produce dual immune response in people aged 18 to 55 years.
Hopes of finding a Covid-19 vaccine have received a big boost after another clinical trial showed good progress.
The ChAdOx1 nCoV-19 vaccine — developed by British-Swedish multinational AstraZeneca in conjunction with University of Oxford — has shown promising results in its final phase of clinical trial.
